FDA Denied the Brand Name 'Xyvona' — Now Sun Pharma Is Recalling the Levorphanol It Already Shipped

Most drug recalls in the openFDA enforcement feed trace back to something gone wrong inside the pill — an impurity, a potency miss, a sterility lapse. The Sun Pharmaceutical Industries recall logged with a report date of June 10, 2026, is a rarer animal: the medicine is fine, but its name is not approved. The recalled product is Xyvona (levorphanol tartrate tablets), 3mg, in 100-tablet bottles, Rx only, branded for Forte BioPharma, manufactured by Ohm Laboratories Inc. of New Brunswick, New Jersey, and distributed by Fort Bio-Pharma, LLC of Las Vegas. The affected stock is lot AE11393, expiring October 2027, distributed nationwide under NDC 72245-058-10.

The recall was firm-initiated and voluntary, with initial notification sent by letter, and the openFDA record lists it as ongoing and Not Yet Classified — meaning FDA had not yet assigned a Class I, II, or III hazard tier when the record posted. The reason is stated plainly, and it is unusual enough to quote in full.

"Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona"— openFDA Drug Enforcement Report, Sun Pharmaceutical Industries, source

How does an FDA brand-name denial become a recall?

Proprietary drug names are not a marketing afterthought — they are a regulated part of the product, reviewed by FDA's Division of Medication Error Prevention and Analysis. The agency screens proposed brand names for the risk that they could be confused with another product, misread in handwriting, or imply an unproven benefit, because name confusion is a documented source of medication errors. A name can be rejected even after a drug's active ingredient and dosage form are otherwise cleared. Levorphanol tartrate is itself a long-established opioid analgesic, so the underlying molecule was never the issue. What FDA declined was the specific proprietary name Xyvona for this product.

When a proposed name is denied after product has already entered distribution, the labeling on the marketed bottles is, by definition, not the labeling FDA authorized — and a drug marketed with unauthorized labeling is misbranded. That is why a naming decision lands in the enforcement database as a labeling recall rather than as a quiet administrative correction. The fix is straightforward in concept: pull the product bearing the rejected name and, if the sponsor wants to continue selling it, return with an approved name or label. But for the company, the logistics and cost of a nationwide retrieval are real, and the commercial timeline for the launch is set back regardless.

The corporate cast, and what it signals about the launch

The enforcement record names a notable chain of parties for a single 3mg tablet. The recalling firm is Sun Pharmaceutical Industries Inc., one of the largest generic and specialty manufacturers in the world. The product is branded for Forte BioPharma; manufactured by Ohm Laboratories, a New Jersey facility long associated with Sun's U.S. operations; and distributed by Fort Bio-Pharma of Las Vegas. That layered structure — a global manufacturer, a small specialty brand, and a separate distributor — is typical of how niche analgesics reach the market, and it means the branding decision sat with the smallest, least-capitalized party in the chain while the recall obligation flows back through the manufacturer of record.

For the deals desk, the read-through is about launch risk rather than safety risk. Levorphanol is a small, specialized opioid market, and bringing a branded version to it depends on differentiation — and a brand name is the most visible piece of that differentiation. A name denial after product has shipped suggests the launch ran ahead of final FDA name clearance, a sequencing risk that small specialty sponsors sometimes accept to compress time to market. The cost is exactly what the openFDA record now documents: a nationwide recall of saleable, in-date inventory that has nothing wrong with it chemically.

Reading the record's limits

The openFDA entry is precise about cause and product but deliberately narrow. It does not say whether Sun and Forte BioPharma intend to relaunch the levorphanol tablet under a different approved name, whether any of the lot AE11393 inventory had reached patients, or what timeline FDA's name denial followed. The recall initiation date is listed as May 22, 2026, with the public posting on June 10 — the familiar few-week lag between firm action and database visibility. Because the action was Not Yet Classified at posting, the eventual hazard tier is unresolved in the record; a labeling-only recall of an otherwise sound product would typically draw a low classification, but the openFDA field had not been finalized.

The broader lesson is that the enforcement feed captures more than contamination. It captures every way a marketed drug can fall out of compliance — including the failure to secure an approved name before shipping. For anyone modeling the commercial path of a small specialty launch, that is a useful reminder: the regulatory gate on a brand name is as binding as the gate on the molecule, and missing it can erase a launch quarter even when the science is sound. Sun's Xyvona recall is, in the end, a branding story wearing the clothes of a safety recall — and a clean illustration of how tightly FDA controls every word on the box.

theradeals follows the regulatory and commercial mechanics behind drug launches, including the often-overlooked decisions — like proprietary naming — that can stall a product after it has already shipped.